These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 20110044)

  • 1. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
    J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH; Dolder CR
    Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
    Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
    Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
    Ravaud A; Hawkins R; Gardner JP; von der Maase H; Zantl N; Harper P; Rolland F; Audhuy B; Machiels JP; Pétavy F; Gore M; Schöffski P; El-Hariry I
    J Clin Oncol; 2008 May; 26(14):2285-91. PubMed ID: 18467719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
    Kroep JR; Linn SC; Boven E; Bloemendal HJ; Baas J; Mandjes IA; van den Bosch J; Smit WM; de Graaf H; Schröder CP; Vermeulen GJ; Hop WC; Nortier JW
    Neth J Med; 2010 Sep; 68(9):371-6. PubMed ID: 20876920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
    Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Andersson M; Kamby C
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.